LONDON – Oxford BioDynamics PLC (LON:), a clinical diagnostics company specializing in precision medicine, has announced a retail offer to raise up to £500,000 through a new share issue. This offer is exclusive to existing qualified shareholders in the United States Kingdom (TADAWUL:) and is conducted through the Winterflood Retail Access Platform (WRAP).
The offer includes up to 100,000,000 new ordinary shares at an issue price of 0.5 pence each. The issue price represents a 44% discount to Sunday’s closing mid-market price of 0.9 pence per ordinary share. Funds raised will be used in a similar way to co-op and subscription proceeds which aim to raise at least £6m.
The retail offer is part of the company’s wider fundraising strategy, which is dependent on shareholder approval at a general meeting scheduled for 31 January 2025 and the subsequent listing of the new shares on the AIM market. London Stock Exchange (LON:). Trading is expected to begin on February 4, 2025.
Oxford BioDynamics is reaching out to its UK retail shareholder base, providing an opportunity to participate in the company’s growth. The minimum subscription per investor is set at £250 and the offer closes at 4.30pm on Thursday this week. Shareholders interested in participating can contact their brokers or wealth managers.
The newly issued ordinary shares will be fully paid and rank equally with the existing ordinary shares, including the right to dividends and other distributions declared after the date of issue.
Investors are reminded that investing in a company carries risks and that capital is at stake. The value of investments may fluctuate, which may result in investors receiving less than their original investment.
This announcement is based on a press release and does not constitute an offer or solicitation in jurisdictions where such actions would violate applicable laws. The offer is not being made in the United States, Australia, Canada, New Zealand, Japan, South Africa, any member state of the EEA or any jurisdiction where it would be illegal. Shares in the retail offering will not be registered under the US Securities Act and are not being offered in the US.
The information provided in this article is for background purposes only and is not intended to be full or complete. It is based on a press release and should be read in conjunction with the company’s full release for a comprehensive understanding of the terms and conditions of the offer.
This article was generated with the support of artificial intelligence and reviewed by an editor. See our T&C for more information.
